Emcure Pharmaceuticals, an Indian pharmaceutical leader, has entered into a key deal worth about €19.7 million. This strategic development highlights Emcure's vision of increasing its international presence and product portfolio. The firm is well known for its wide-ranging portfolio of pharma products ranging from orals and injectables to biotherapeutics, which are sold in more than 70 countries worldwide. Emcure has just finished a successful IPO, raising ₹1,952 crore for enhancing its financial position to nurture future growth opportunities. This new transaction is in sync with Emcure's commitment towards innovation and sustainability, as seen through its recent solar power deal aimed at minimizing its carbon footprint.
Source: Business Standard, Deccan Herald, NDTV Profit.